Bristol-Myers Squibb Company (BRM.DE)
XETRA - XETRA Delayed price. Currency in EUR
Add to watchlist
At close: 05:35PM CEST
| Previous close | 39.46 |
| Open | 39.38 |
| Bid | 39.83 x 37000 |
| Ask | 39.88 x 43000 |
| Day's range | 39.38 - 40.08 |
| 52-week range | 36.90 - 59.70 |
| Volume | |
| Avg. volume | 4,812 |
| Market cap | 80.78B |
| Beta (5Y monthly) | 0.43 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.89 |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | 2.23 (5.66%) |
| Ex-dividend date | 05 Jul 2024 |
| 1y target est | N/A |
ZacksBristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $42.19, denoting a -0.09% change from the preceding trading day.
ZacksBristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer
Bristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer.
Business WireBristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
PRINCETON, N.J., June 21, 2024--Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with...
© 2024 Yahoo. All rights reserved.